Impax Laboratories gets tenders of 99.9% of 2% convertibles due 2022

By Wendy Van Sickle

Columbus, Ohio, June 5 – Impax Laboratories, Inc. said $599,376,000, or 99.9%, of its 2% senior convertible notes due 2022 were tendered by the deadline of its cash offer to repurchase any and all of the notes.

The offer expired at 11:59 p.m. ET on June 4.

All of the tendered notes will be accepted at a purchase price of par plus accrued interest to but excluding June 15, according to a press release.

Payment was expected to be made on June 5.

RBC Capital Markets (212 618-7843 or 877 381-2099) is the dealer manager.

Global Bondholder Services Corp. acted as the information agent and depositary.

Impax is a specialty pharmaceutical company based in Hayward, Calif. It is a wholly owned subsidiary of Amneal Pharmaceuticals, Inc., a Bridgewater, N.J.-based generic pharmaceutical manufacturer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.